PF-04457845FAAH inhibitor,potent and exquisitely selective CAS# 1020315-31-4 |
- PF-3845
Catalog No.:BCC2326
CAS No.:1196109-52-0
- FAAH inhibitor 1
Catalog No.:BCC4254
CAS No.:326866-17-5
- URB597
Catalog No.:BCC2324
CAS No.:546141-08-6
- JNJ-1661010
Catalog No.:BCC2315
CAS No.:681136-29-8
- LY2183240
Catalog No.:BCC1718
CAS No.:874902-19-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1020315-31-4 | SDF | Download SDF |
PubChem ID | 24771824 | Appearance | Powder |
Formula | C23H20F3N5O2 | M.Wt | 455.43 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (219.57 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide | ||
SMILES | C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4 | ||
Standard InChIKey | BATCTBJIJJEPHM-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | PF-04457845 is a potent and exquisitely selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH) with an IC50 value of 7.2 nM. | |||||
Targets | FAAH | |||||
IC50 | 7.2 nM |
PF-04457845 Dilution Calculator
PF-04457845 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1957 mL | 10.9786 mL | 21.9573 mL | 43.9145 mL | 54.8932 mL |
5 mM | 0.4391 mL | 2.1957 mL | 4.3915 mL | 8.7829 mL | 10.9786 mL |
10 mM | 0.2196 mL | 1.0979 mL | 2.1957 mL | 4.3915 mL | 5.4893 mL |
50 mM | 0.0439 mL | 0.2196 mL | 0.4391 mL | 0.8783 mL | 1.0979 mL |
100 mM | 0.022 mL | 0.1098 mL | 0.2196 mL | 0.4391 mL | 0.5489 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PF-04457845 Description:
IC50: Kinact/Ki and IC50 values of 40300 M-1 s-1 and 7.2 nM, respectively, for human FAAH [1].
Fatty acid amide hydrolase or FAAH is a member of the serine hydrolase family of enzymes. It was first shown to break down anandamide in 1993. PF-04457845 is a potent and exquisitely selective inhibitor of the FAAH, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen (http://en.wikipedia.org/wiki/PF-04457845).
In vitro: Mechanistic studies confirm that PF-04457845 is a time-dependent, covalent FAAH inhibitor that carbamylates FAAH's catalytic serine nucleophile. PF-04457845 inhibits human FAAH with high potency and is exquisitely selective in vivo as determined by activity-based protein profiling. [2].
In vivo: Oral administration of PF-04457845 produced potent antinociceptive effects in both inflammatory and noninflammatory pain models in rats, with a minimum effective dose of 0.1 mg/kg. PF-04457845 also displayed a long duration of action as a single oral administration at 1 mg/kg showed in vivo efficacy for 24 h with a concomitant near-complete inhibition of FAAH activity and maximal sustained elevation of anandamide in brain. Significantly, PF-04457845-treated mice at 10 mg/kg elicited no effect in motility, catalepsy, and body temperature. These data suggest PF-04457845 is a clinical candidate for the treatment of pain and other nervous system disorders. [2].
Clinical trial: A clinical trial was approved to evaluate the pharmacology and tolerability of PF-04457845 in healthy subjects. Results showed that FAAH1 activity was almost completely inhibited (>97%) following doses of at least 0.3 mg (single dose) and 0.5 mg once daily (multiple dose) PF-04457845. Mean fatty acid amide concentrations increased (3.5- to 10-fold) to a plateau and then were maintained following PF-04457845. FAAH1 activity and fatty acid amide concentrations returned to baseline within 2 weeks following cessation of dosing at doses up to 4 mg. There was no evidence of effects of PF-04457845 on cognitive function. PF-04457845, at doses up to 40 mg single dose and 8 mg once daily for 14 days, was well tolerated. These data indicated PF-04457845 was well tolerated at doses exceeding those required for maximal inhibition of FAAH1 activity and elevation of fatty acid amides.
Reference:
[1] Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, Beidler D, Liimatta MB, Smith SE, Dudley DT, Sadagopan N, Bhattachar SN, Kesten SJ, Nomanbhoy TK, Cravatt BF, Ahn K. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011;2(2):91-96.
[2] Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, Young T, Wren P, Zhang Y, Swaney S, Van Becelaere K, Blankman JL, Nomura DK, Bhattachar SN, Stiff C, Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther. 2011;338(1):114-24.
- (R)-4-Benzyl-2-oxazolidinone
Catalog No.:BCC8395
CAS No.:102029-44-7
- DCC-2036 (Rebastinib)
Catalog No.:BCC4390
CAS No.:1020172-07-9
- SGI-1027
Catalog No.:BCC4588
CAS No.:1020149-73-8
- 20,24-Epoxy-24-methoxy-23(24-25)abeo-dammaran-3-one
Catalog No.:BCN1639
CAS No.:1020074-97-8
- Sulfaclozine
Catalog No.:BCC9155
CAS No.:102-65-8
- Phenyethyl 3-methylcaffeate
Catalog No.:BCN8457
CAS No.:71835-85-3
- 3,4-Dihydroxyphenylacetic Acid
Catalog No.:BCC8281
CAS No.:102-32-9
- Acetoacetanilide
Catalog No.:BCC8803
CAS No.:102-01-2
- GW791343 dihydrochloride
Catalog No.:BCC1613
CAS No.:1019779-04-4
- Zardaverine
Catalog No.:BCC2069
CAS No.:101975-10-4
- Octacosyl (E)-ferulate
Catalog No.:BCN5834
CAS No.:101959-37-9
- S0859
Catalog No.:BCC1914
CAS No.:1019331-10-2
- Protosappanin A
Catalog No.:BCN7259
CAS No.:102036-28-2
- Protosappanin B
Catalog No.:BCN2281
CAS No.:102036-29-3
- Tubeimoside I
Catalog No.:BCN1089
CAS No.:102040-03-9
- 3-Deazaneplanocin,DZNep
Catalog No.:BCC1129
CAS No.:102052-95-9
- Arctinol B
Catalog No.:BCN5835
CAS No.:102054-39-7
- Sappanone A
Catalog No.:BCN2996
CAS No.:102067-84-5
- Boc-D-Phenylglycinol
Catalog No.:BCC2711
CAS No.:102089-74-7
- 3-(4-Hydroxyphenyl)-1-propanol
Catalog No.:BCN5836
CAS No.:10210-17-0
- Pseudoproto Pb
Catalog No.:BCN2838
CAS No.:102100-46-9
- Pseudoprotodioscin
Catalog No.:BCN2827
CAS No.:102115-79-7
- Cyclocytidine HCl
Catalog No.:BCC5555
CAS No.:10212-25-6
- rac-Rotigotine Hydrochloride
Catalog No.:BCC1881
CAS No.:102120-99-0
Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.[Pubmed:22044402]
Br J Clin Pharmacol. 2012 May;73(5):706-16.
UNLABELLED: AIMS To evaluate the pharmacology and tolerability of PF-04457845, an orally available fatty acid amide hydrolase-1 (FAAH1) inhibitor, in healthy subjects. METHODS: Double-blind, randomized, placebo-controlled single and multiple rising dose studies and an open-label, randomized, food effect study were conducted. Plasma and urine PF-04457845 concentrations, plasma fatty acid amide concentrations and FAAH1 activity in human leucocytes were measured. Tolerability, including effects on cognitive function, were assessed. RESULTS: PF-04457845 was rapidly absorbed (median t(max) 0.5-1.2 h). Exposure increased supraproportionally to dose from 0.1 to 10 mg and proportionally between 10 and 40 mg single doses. The pharmacokinetics appeared dose proportional following 14 days once daily dosing between 0.5 and 8 mg. Steady-state was achieved by day 7. Less than 0.1% of the dose was excreted in urine. Food had no effect on PF-04457845 pharmacokinetics. FAAH1 activity was almost completely inhibited (>97%) following doses of at least 0.3 mg (single dose) and 0.5 mg once daily (multiple dose) PF-04457845. Mean fatty acid amide concentrations increased (3.5- to 10-fold) to a plateau and then were maintained following PF-04457845. FAAH1 activity and fatty acid amide concentrations returned to baseline within 2 weeks following cessation of dosing at doses up to 4 mg. There was no evidence of effects of PF-04457845 on cognitive function. PF-04457845, at doses up to 40 mg single dose and 8 mg once daily for 14 days, was well tolerated. CONCLUSIONS: PF-04457845 was well tolerated at doses exceeding those required for maximal inhibition of FAAH1 activity and elevation of fatty acid amides.
An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee.[Pubmed:22727500]
Pain. 2012 Sep;153(9):1837-46.
The effect of PF-04457845, a potent and selective fatty acid amide hydrolase-1 (FAAH1) inhibitor, on pain due to osteoarthritis of the knee was investigated in a randomised placebo and active-controlled clinical trial. The trial involved 2 periods (separated by a 2-week washout) consisting of a 1-week wash-in phase followed by 2weeks double-blind treatment. Patients received single-blind placebo throughout the wash-in and washout periods. Patients were randomised to receive either 4mg q.d. PF-04457845 followed by placebo (or vice versa), or 500mg b.i.d. naproxen followed by placebo (or vice versa). The primary end point was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score. The trial had predefined decision rules based on likelihood that PF-04457845 was better or worse than the standard of care (considered to be a 1.8 reduction in WOMAC pain score compared to placebo). A total of 74 patients were randomised to 1 of 4 treatment sequences. The mean differences (80% confidence intervals) from placebo in WOMAC pain score were 0.04 (-0.63 to 0.71) for PF-04457845 and -1.13 (-1.79 to -0.47) for naproxen, indicating that whilst naproxen seemed efficacious, PF-04457845 was not differentiated from placebo. The study was stopped at the interim analysis for futility. PF-04457845 decreased FAAH activity by >96% and substantially increased 4 endogenous substrates (fatty acid amides). PF-04457845 was well tolerated in osteoarthritis patients, and there was no evidence of cannabinoid-type adverse events. The lack of analgesic effect of FAAH1 inhibition in humans is in contrast to data from animal models. This apparent disconnect between species needs further study.
Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase.[Pubmed:23731552]
Nucl Med Biol. 2013 Aug;40(6):740-6.
INTRODUCTION: Fatty acid amide hydrolase (FAAH) has a significant role in regulating endocannabinoid signaling in the central nervous system. As such, FAAH inhibitors are being actively sought for pain, addiction, and other indications. This has led to the recent pursuit of positron emission tomography (PET) radiotracers targeting FAAH. We report herein the preparation and preclinical evaluation of [(11)C-carbonyl]PF-04457845, an isotopologue of the potent irreversible FAAH inhibitor. METHODS: PF-04457845 was radiolabeled at the carbonyl position via automated [(11)C]CO(2)-fixation. Ex vivo brain biodistribution of [(11)C-carbonyl]PF-04457845 was carried out in conscious rats. Specificity was determined by pre-administration of PF-04457845 or URB597 prior to [(11)C-carbonyl]PF-04457845. In a separate experiment, rats injected with the title radiotracer had whole brains excised, homogenized and extracted to examine irreversible binding to brain parenchyma. RESULTS: The title compound was prepared in 5 +/- 1% (n = 4) isolated radiochemical yield based on starting [(11)C]CO(2) (decay uncorrected) within 25 min from end-of-bombardment in >98% radiochemical purity and a specific activity of 73.5 +/- 8.2 GBq/mumol at end-of-synthesis. Uptake of [(11)C-carbonyl]PF-04457845 into the rat brain was high (range of 1.2-4.4 SUV), heterogeneous, and in accordance with reported FAAH distribution. Saturable binding was demonstrated by a dose-dependent reduction in brain radioactivity uptake following pre-treatment with PF-04457845. Pre-treatment with the prototypical FAAH inhibitor, URB597, reduced the brain radiotracer uptake in all regions by 71-81%, demonstrating specificity for FAAH. The binding of [(11)C-carbonyl]PF-04457845 to FAAH at 40 min post injection was irreversible as 98% of the radioactivity in the brain could not be extracted. CONCLUSIONS: [(11)C-carbonyl]PF-04457845 was rapidly synthesized via an automated radiosynthesis. Ex vivo biodistribution studies in conscious rodents demonstrate that [11C PF-04457845 is a promising candidate radiotracer for imaging FAAH in the brain with PET. These results coupled with the known pharmacology and toxicology of PF-04457845 should facilitate clinical translation of this radiotracer.
Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11)C]CURB.[Pubmed:26082009]
J Cereb Blood Flow Metab. 2015 Nov;35(11):1827-35.
Positron emission tomography with [(11)C]CURB was recently developed to quantify fatty acid amide hydrolase (FAAH), the enzyme responsible for hydrolyzing the endocannabinoid anandamide. This study investigated the test-retest reliability of [(11)C]CURB as well as its in vivo specificity and the validity of the kinetic model by using the highly specific FAAH inhibitor, PF-04457845. Five healthy volunteers completed test-retest [(11)C]CURB scans 1 to 2 months apart and six subjects completed baseline and blocking scans on the same day after PF-04457845 (p.o.) administration (1, 4, or 20 mg; n=2 each). The composite parameter lambdak3 (an index of FAAH activity, lambda=K1/k2) was estimated using an irreversible two-tissue compartment model with plasma input function. There were no clinically observable responses to oral PF-04457845 or [(11)C]CURB injection. Oral administration of PF-04457845 reduced [(11)C]CURB binding to a homogeneous level at all three doses, with lambdak3 values decreased by 91%. Excellent reproducibility and good reliability (test-retest variability=9%; intraclass correlation coefficient=0.79) were observed across all regions of interest investigated. Our findings suggest that lambdak3/[(11)C]CURB is a reliable, highly sensitive, and selective tool to measure FAAH activity in human brain in vivo. Moreover, PF-04457845 is a highly potent FAAH inhibitor (>95% inhibition at 1 mg) in living human brain.